Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection

  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Felip, Eudald|||0000-0002-3812-1313
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Calba, Ignasi
  • Massanella, Marta|||0000-0002-3326-151X
  • Sirera, Guillem|||0000-0003-4014-9355
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • Badia, Roger|||0000-0003-3982-7577
HIV latent infection may be associated with disrupted viral RNA sensing, interferon (IFN) signaling, and/or IFN stimulating genes (ISG) activation. Here, we evaluated the use of compounds selectively targeting at the inhibitor of nuclear factor-κB (IκB) kinase (IKK) complex subunits and related kinases (TBK1) as a novel pathway to reverse HIV-1 latency in latently infected non-clonal lymphoid and myeloid cell in vitro models. IKK inhibitors (IKKis) triggered up to a 1.8-fold increase in HIV reactivation in both, myeloid and lymphoid cell models. The best-in-class IKKis, targeting TBK-1 (MRT67307) and IKKβ (TCPA-1) respectively, were also able to significantly induce viral reactivation in CD4+ T cells from people living with HIV (PLWH) ex vivo. More importantly, although none of the compounds tested showed antiviral activity, the combination of the distinct IKKis with ART did not affect the latency reactivation nor blockade of HIV infection by ART. Finally, as expected, IKKis did not upregulate cell activation markers in primary lymphocytes and innate immune signaling was blocked, resulting in downregulation of inflammatory cytokines. Overall, our results support a dual role of IKKis as immune modulators being able to tackle the HIV latent reservoir in lymphoid and myeloid cellular models and putatively control the hyperinflammatory responses in chronic HIV-1 infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Felip, Eudald|||0000-0002-3812-1313
  • Castellà Fernández, Eva
  • Quiroga García, Vanesa
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Angelats, Laura
  • Esteve, Anna|||0000-0002-1962-971X
  • Pérez-Roca, Laia|||0000-0002-8400-1339
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Fernandez, Pedro Luis
  • Ferrando Díez, Angelica|||0000-0003-0206-7498
  • Pous, Anna
  • Bergamino, Milana|||0000-0002-1091-2711
  • Cirauqui, Beatriz|||0000-0002-0136-8056
  • Romeo, Marga
  • Teruel, Iris|||0000-0002-5563-6562
  • Mesia, Ricard|||0000-0002-3785-3563
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
The lack of validated surrogate biomarkers is still an unmet clinical need in the management of early breast cancer cases that do not achieve complete pathological response after neoadjuvant chemotherapy (NACT). Here, we describe and validate the use of SAMHD1 expression as a prognostic biomarker in residual disease in vivo and in vitro. SAMHD1 expression was evaluated in a clinical cohort of early breast cancer patients with stage II-III treated with NACT. Heterotypic 3D cultures including tumor and immune cells were used to investigate the molecular mechanisms responsible of SAMHD1 depletion through whole transcriptomic profiling, immune infiltration capacity and subsequent delineation of dysregulated immune signaling pathways. SAMHD1 expression was associated to increased risk of recurrence and higher Ki67 levels in post-NACT tumor biopsies of breast cancer patients with residual disease. Survival analysis showed that SAMHD1-expressing tumors presented shorter time-to-progression and overall survival than SAMHD1 negative cases, suggesting that SAMHD1 expression is a relevant prognostic factor in breast cancer. Whole-transcriptomic profiling of SAMHD1-depleted tumors identified downregulation of IL-12 signaling pathway as the molecular mechanism determining breast cancer prognosis. The reduced interleukin signaling upon SAMHD1 depletion induced changes in immune cell infiltration capacity in 3D heterotypic in vitro culture models, confirming the role of the SAMHD1 as a regulator of breast cancer prognosis through the induction of changes in immune response and tumor microenvironment. SAMHD1 expression is a novel prognostic biomarker in early breast cancer that impacts immune-mediated signaling and differentially regulates inflammatory intra-tumoral response. The online version contains supplementary material available at 10.1007/s13402-023-00862-1.